Moreover, the deletion of ARID1A in the tumor microenvironment activates cancer-associated fibroblasts and drives the proliferation and migration of lung cancer cells, but inhibits tumor cell autophagy and enhances the sensitivity of immunosuppressive therapy for EGFR-mutant lung adenocarcinoma [165, 166]. Here, ARID1A is linked to neoplasm.